OneMedNet Secures $11.5+ Million Agreement to Supply Regulatory-Grade Real-World Data for Foundational AI Model Development
Rhea-AI Summary
OneMedNet (Nasdaq: ONMD) entered into an agreement valued at more than $11.5 million to supply its regulatory-grade, multi-modal, imaging-centric iRWD™ healthcare data for development and training of a foundational AI model. Data delivery is set to begin immediately and includes millions of de-identified medical images and associated clinical reports.
According to OneMedNet, this deal leverages its AI-powered iRWD™ platform and anonymized federated network, which provides live, longitudinal access to private healthcare data. The company reports commercial momentum supported by a network exceeding 90 million patient journeys, 270 million clinical studies, and more than 2,300 healthcare sites.
Positive
- Contract value >$11.5 million for supplying regulatory-grade iRWD™ data
- Network exceeds 90 million patient journeys, 270 million studies, across >2,300 sites
Negative
- None.
News Explained
OneMedNet has entered a
Sources and calculations
- OneMedNet agreement announcement (2026-07-28)
- OneMedNet first-quarter financials (2026Q1)
- Cash and equivalents vs quarterly operating cash outflow, in days of cash use $233,000 / ($1,542,000 / 90) = [object Object]
Market reaction after AI data contract: ONMD +17.02% in the Jul 28 session
In the Jul 28 session, ONMD gained 17.02%, reflecting a significant positive market reaction. Argus tracked a peak move of +70.2% during that session. Argus tracked a trough of -23.7% from its starting point during tracking. Our momentum scanner triggered 136 alerts that day, indicating very high trading interest and price volatility. Trading volume was exceptionally heavy at 151.4x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous AI Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 06 | 2025 AI financials | Positive | +2.4% | Reported 2025 financial results and AI platform progress, including revenue and liability metrics. |
| Apr 01 | Oncology AI collaboration | Positive | -0.8% | Announced collaboration using real-world data and AI for oncology development. |
| Jan 22 | FDA 510(k) clearance | Positive | +12.1% | Real-world data supported FDA clearance of AI-powered intracranial hemorrhage software. |
| Nov 10 | AI subscription launch | Positive | +4.7% | Presented subscription platform with live data feeds and conversational AI search. |
| Oct 06 | Palantir AI partnership | Positive | +148.5% | Selected Palantir for multi-year healthcare AI and data analytics integration. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-tagged news historically showed mostly positive price alignment, with four aligned reactions and one divergence.
Key Terms
real-world data medical
de-identified medical
federated network technical
foundational ai model technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Validates OneMedNet’s Position as Premier Supplier of High-Quality Healthcare Data for Advanced AI Training.
MINNEAPOLIS, July 28, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of regulatory decision-grade, AI-driven Real-World Data (RWD), today announced it has entered into an agreement to supply its regulatory-grade, multi-modal imaging-centric iRWD™ platform data for use in the development and training of a foundational AI model.
Under the terms of the agreement, OneMedNet will provide high-quality, de-identified, regulatory-grade healthcare data, including millions of medical imaging and associated clinical reports, with data delivery immediately. The initial agreement has a total contract value in excess of
"We believe this agreement represents a significant validation of OneMedNet's unique capabilities in curating and delivering regulatory decision-grade Real-World Data at the scale and quality required for foundational AI model development. OneMedNet is uniquely positioned to deliver fully de-identified, regulatory-grade datasets through our secure, anonymized federated network of live data, enabling breakthrough AI innovation while upholding the highest standards of patient privacy and compliance. Our AI-powered iRWD™ platform, combined with our expansive provider network, makes this possible at the speed, scale, and quality that modern healthcare demands,” said Aaron Green, CEO & President of OneMedNet.
"Private data is what we believe will ultimately differentiate one foundational model from another—and healthcare data is among the most private and valuable. OneMedNet's delivery platform provides live, longitudinal access to this data, with in-flight anonymization built in," stated Jeffrey Yu, MD, Chairman of OneMedNet.”
This agreement is expected to build on OneMedNet’s strong commercial momentum and expanding network, which now surpasses 90 million patient journeys and 270 million clinical studies across more than 2,300 healthcare sites. This network continues to expand in scope and depth. The Company’s iRWD™ platform, enables secure, scalable delivery of multi-modal data optimized for AI training, regulatory submissions, and advanced analytics.
About OneMedNet Corporation
OneMedNet Corporation is revolutionizing Real-World Data (RWD) through its iRWD™ platform, delivering regulatory decision-grade, AI-ready datasets that include de-identified medical imaging alongside comprehensive clinical records. With a network spanning more than 2,300 sites and encompassing over 90 million patient journeys and 270 million studies, OneMedNet serves life sciences companies, medical device manufacturers, AI developers, and other innovators seeking high-quality, compliant healthcare data. The Company’s platform is powered by Palantir Foundry and supports applications ranging from drug development and regulatory submissions to foundational AI model training. Learn more at www.onemednet.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements. These statements include, but are not limited to, statements regarding our ability to convert bookings into revenue and the demand for our products, our ability to achieve our operational strategies, our expected growth in the business and statements generally about our products, plans and strategies.
Forward-looking statements are based on information available at the time those statements are made and were based on current expectations as well as the beliefs and assumptions of management as of that time with respect to future events. These statements are subject to risks and uncertainties, many of which involve factors or circumstances that are beyond our control. These risks and uncertainties include, but are not limited to: our ability to change the direction of OneMedNet; our ability to keep pace with new technology and changing market needs; the competitive environment of our business; risks inherent with investing in Digital Assets, including Digital Asset’s volatility; our ability to implement our Digital Asset treasury strategy and its effects on our business; and the other risks described in our most recent Annual Report on Form 10-K and our subsequent filings with the Securities and Exchange Commission. Except as required by law, we do not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise.
OneMedNet Contacts:
Michael Wong, VP Marketing
Email: michael.wong@onemednet.com
SOURCE: ONEMEDNET CORPORATION
